Cisplatin, radiation, and amifostine in carcinoma of the uterine cervix

This publication has 21 references indexed in Scilit:

• Long-Term Follow-up of the First Randomized Trial Using Neoadjuvant Chemotherapy in Stage Ib Squamous Carcinoma of the Cervix: The Final Results
  Gynecologic Oncology, 1997
• Epidemiología descriptiva de cáncer en el Instituto Nacional de Cancerología de México
  Salud Pública de México, 1997
• Cancer of the Uterine Cervix
  New England Journal of Medicine, 1996
• 110 Phase II clinical trial of amifostine (WR2721), cisplatin (C), vinblastine (V) (ACV) and thoracic radiation therapy (RT) for unresectable stage III non small cell lung cancer (NSCLC).
  International Journal of Radiation Oncology*Biology*Physics, 1995
• 500 Amifostine (AMI) selectively protects against cumulative toxicities of cyclophosphamide (C) and cisplatin (P)
  European Journal Of Cancer, 1995
• Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate
  Biochemical Pharmacology, 1992
• Induction chemotherapy followed by radical surgery in cervical cancer
  Gynecologic Oncology, 1991
• Comprehensive Criteria for Assessing Therapy-Induced Toxicity
  Cancer Investigation, 1989
• Preoperative adjuvant chemotherapy in the treatment of cervical cancer stage Ib, IIa, and IIb with bulky tumor
  Gynecologic Oncology, 1988
• Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer
  BJOG: An International Journal of Obstetrics and Gynaecology, 1987